ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial-宜明昂科英文

Company News

Home Company News News detail

ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial

2025-01-13

1322

Previous article：Approval by the NMPA for Clinical Trial of IMM01 (timdarpacept) Combined with IMM2510 (palverafusp α) and with or without Chemotherapy for Advanced Malignant Tumors

Next article：The Phase II clinical trial of IMM27M for estrogen receptor positive (ER+) advanced breast cancer that failed after endocrine therapy or recurred and has enrolled the first patient

Hot recommendation

ImmuneCare, a Subsidiary of ImmuneOnco, Files Patent for IMC-015 Bispecific Antibody Differentiated "Fat-Loss & Muscle-Gain" Strategy Poised to Tackle GLP-1-Induced Muscle Loss

ImmuneOnco Presents at J.P. Morgan Healthcare Conference: Biotech Showcase™ Presentation Highlights Progress of Core Programs Including IMM01

ImmuneCare, a Subsidiary of ImmuneOnco, Successfully Completes Subject Enrollment for First Cohort in MAD Study of IMC-003 for Pulmonary Arterial Hypertension

For more information

Please follow the official wechat public account